The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.50
Bid: 19.00
Ask: 20.00
Change: 0.00 (0.00%)
Spread: 1.00 (5.263%)
Open: 19.50
High: 19.50
Low: 19.50
Prev. Close: 19.50
RENX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

26 Nov 2020 07:01

RNS Number : 5461G
Renalytix AI PLC
26 November 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Renalytix AI Plc

213800NTOH3FK3WER551

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

 

EKF Diagnostics Holdings Plc

 

City and country of registered office (if applicable)

Avon House, 19 Stanwell Road, Penarth, Cardiff, CF64 2EZ

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

 

24 November 2020

 

6. Date on which issuer notified (DD/MM/YYYY):

 

25 November 2020

 

 

7. Total positions of person(s) subject to the notification obligation

 

 

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

Below 3%

-

Below 3%

72,029,634

Position of previous notification (if

applicable)

3.72%

-

3.72%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BYWL4Y04

Below 3%

-

Below 3%

-

SUBTOTAL 8. A

Below 3%

Below 3%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

 

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

x

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

EKF Diagnostics Holdings Plc (Direct/Indirect)

Below 3%

Below 3%

 

 

 

 

 

10. In case of proxy voting, please identify:

 

Name of the proxy holder

N/A

 

The number and % of voting rights held

N/A

 

The date until which the voting rights will be held

N/A

 

 

 

 

11. Additional informationxvi

 

 

Notification using the total voting rights figure of 72,029,634

 

 

Place of completion

London Stock Exchange

Date of completion

25/11/2020

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFZMZMMKFGGZZ
Date   Source Headline
8th Jun 20233:30 pmRNSResult of General Meeting
5th Jun 20237:00 amRNSNotice of Q3 Results
25th May 20237:00 amRNSEVERSANA® partnership for KidneyIntelX
22nd May 20237:00 amRNSExpansion of insurance coverage for KidneyIntelX
11th May 20237:00 amRNSNotice of GM and Posting of Circular
19th Apr 20237:00 amRNSReal-World Evidence Shows KidneyIntelX™ Utility
12th Apr 20237:00 amRNSPositive Data Release at NKF Conference
30th Mar 20237:00 amRNSHalf-year Report
27th Mar 202312:50 pmRNSBusiness Update - Replacement
27th Mar 20237:00 amRNSBusiness Update
22nd Mar 20237:00 amRNSNotice of Results
21st Mar 20232:05 pmRNSSecond Price Monitoring Extn
21st Mar 20232:00 pmRNSPrice Monitoring Extension
21st Mar 20237:00 amRNSUpdate on FDA De Novo Authorization Process
13th Mar 20237:00 amRNSStatement re. Silicon Valley Bank
7th Mar 20237:00 amRNSIssue of Shares
10th Feb 20233:13 pmRNSHolding(s) in Company
10th Feb 20232:01 pmRNSDirector/PDMR Shareholding
9th Feb 20237:00 amRNSRENX to Participate in the BTIG MedTech Conference
8th Feb 20237:00 amRNSRenalytix announces a c.$20.3m private placement
26th Jan 20237:00 amRNSRenalytix and Partners Awarded $10 Million Grant
9th Jan 202311:05 amRNSSecond Price Monitoring Extn
9th Jan 202311:00 amRNSPrice Monitoring Extension
9th Jan 20237:00 amRNSCompletes Agreement with Veterans Administration
19th Dec 202212:01 pmRNSResult of AGM
1st Dec 20227:00 amRNSClinical utility study data: further highlights
30th Nov 20227:00 amRNSResults for First Quarter of Fiscal Year 2023
29th Nov 20227:00 amRNSPublication of new real world evidence
22nd Nov 20227:00 amRNSNotice of Q1 FY23 Results
10th Nov 20227:00 amRNSPublication of Annual Report 2022 & Notice of AGM
9th Nov 20224:35 pmRNSPrice Monitoring Extension
3rd Nov 20227:00 amRNSRENX to Present at Stifel Healthcare Conference
31st Oct 20224:41 pmRNSSecond Price Monitoring Extn
31st Oct 20224:36 pmRNSPrice Monitoring Extension
31st Oct 20227:00 amRNSRenalytix Reports Full Year Fiscal 2022 Results
26th Oct 20229:05 amRNSSecond Price Monitoring Extn
26th Oct 20229:00 amRNSPrice Monitoring Extension
25th Oct 20227:00 amRNSKidneyIntelX Medicare Update
24th Oct 20227:00 amRNSNotice of Results
17th Oct 20227:00 amRNSPresentations accepte at ASN Kiney Week
17th Oct 20227:00 amRNSPresentations accepted at ASN Kidney Week
20th Sep 20227:50 amRNSDirectorate Change
12th Sep 20227:00 amRNSIssue of shares
8th Sep 20227:00 amRNSRenalytix to Present at H.C. Wainwright Conference
17th Aug 202212:00 pmRNSBusiness update
8th Aug 20227:00 amRNSPublication of clinical utility study in The AJMC
30th Jun 20227:00 amRNSRenalytix Reports Financial Results for Q3 of FY22
23rd Jun 20227:00 amRNSRenalytix to Report Financial Results for Q3
10th Jun 20227:00 amRNSMount Sinai clinical utility data
8th Jun 20227:00 amRNSRenalytix to Present at Growth Stock Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.